DNA methylation as a universal biomarker

Cell-free circulating DNA carries not only tumor-specific changes in its sequence but also distinctive epigenetic marks, namely DNA methylation, in certain GC-rich fragments. These fragments are usually located within the promoters and first exons of many genes, comprising CpG islands. Analysis of DNA methylation using cell-free circulating DNA can facilitate development of very accurate biomarkers for detection, diagnosis, prediction of response to therapy and prognosis of outcomes. Recent data suggest that benign and inflammatory diseases have very specific methylation patterns within cell-free circulating DNA, which are different from the pattern of a malignant tumor of the same organ. In addition, specific methylation patterns have been detected for cancers of different organs, so a differential diagnosis of site-specific cancer appears feasible. Currently, cancer-related applications dominate the field, although methylation-based biomarkers may also be possible for other diseases, including neurodegenerative and psychiatric disorders.

[1]  S. Clark,et al.  Cytosines adjacent to methylated CpG sites can be partially resistant to conversion in genomic bisulfite sequencing leading to methylation artifacts. , 1998, Analytical biochemistry.

[2]  J. Nevins,et al.  Genomic and Molecular Profiling Predicts Response to Temozolomide in Melanoma , 2009, Clinical Cancer Research.

[3]  A. Hölscher,et al.  Death-Associated Protein Kinase (DAPK) Promoter Methylation and Response to Neoadjuvant Radiochemotherapy in Esophageal Cancer , 2009, Annals of Surgical Oncology.

[4]  K. Miller,et al.  DNA‐Based Detection of Prostate Cancer in Blood, Urine, and Ejaculates , 2001, Annals of the New York Academy of Sciences.

[5]  J. Foekens,et al.  DNA Methylation Markers Predict Outcome in Node-Positive, Estrogen Receptor-Positive Breast Cancer with Adjuvant Anthracycline-Based Chemotherapy , 2009, Clinical Cancer Research.

[6]  C. Balañà,et al.  Serum DNA as a tool for cancer patient management. , 2003, Roczniki Akademii Medycznej w Bialymstoku.

[7]  J. Ellinger,et al.  Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. , 2008, The Journal of urology.

[8]  S. O’Day,et al.  Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. , 2006, Cancer research.

[9]  A. Noor,et al.  Peptidyl argininedeiminase 2 CpG island in multiple sclerosis white matter is hypomethylated , 2007, Journal of neuroscience research.

[10]  P. Laird,et al.  MethyLight: a high-throughput assay to measure DNA methylation. , 2000, Nucleic acids research.

[11]  John W M Martens,et al.  Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. , 2005, Cancer research.

[12]  W. Steinberg.  The clinical utility of the CA 19-9 tumor-associated antigen. , 1990, The American journal of gastroenterology.

[13]  N. Zawia,et al.  Epigenetics, oxidative stress, and Alzheimer disease. , 2009, Free radical biology & medicine.

[14]  C. Lendon,et al.  A common biological mechanism in cancer and Alzheimer's disease? , 2009, Current Alzheimer research.

[15]  D. Scholtens,et al.  Differential methylation profile of ovarian cancer in tissues and plasma. , 2009, The Journal of molecular diagnostics : JMD.

[16]  T. Huang,et al.  Methylated DNA immunoprecipitation and microarray-based analysis: detection of DNA methylation in breast cancer cell lines. , 2009, Methods in molecular biology.

[17]  Robert Brown,et al.  Aberrant DNA Methylation in Ovarian Cancer , 2003 .

[18]  J. Segars,et al.  Imprinting disorders and assisted reproductive technology , 2010, Current opinion in endocrinology, diabetes, and obesity.

[19]  A. Brodbelt,et al.  Molecular Diagnostics , 2011, Human Genomics.

[20]  Wun-Jae Kim,et al.  Epigenetic markers as promising prognosticators for bladder cancer , 2009, International journal of urology : official journal of the Japanese Urological Association.

[21]  B. Garcia,et al.  Modern approaches for investigating epigenetic signaling pathways. , 2010, Journal of applied physiology.

[22]  K. Husgafvel‐Pursiainen,et al.  Promoter hypermethylation in tumour suppressor genes and response to interleukin-2 treatment in bladder cancer: a pilot study , 2010, Journal of Cancer Research and Clinical Oncology.

[23]  Y. Chawla,et al.  Methylation profiling of tumor suppressor genes and oncogenes in hepatitis virus-related hepatocellular carcinoma in northern India. , 2009, Cancer genetics and cytogenetics.

[24]  Kazuhiro Yoshida,et al.  Melanoma-associated antigen-A1 expression predicts resistance to docetaxel and paclitaxel in advanced and recurrent gastric cancer. , 2007, Oncology reports.

[25]  D. Hoon,et al.  Circulating nucleic acids in plasma and serum: past, present and future. , 2004, Current opinion in molecular therapeutics.

[26]  Sun-Chong Wang,et al.  Age-Specific Epigenetic Drift in Late-Onset Alzheimer's Disease , 2008, PloS one.

[27]  H. Prydz,et al.  An improved method for detection of 5-methylcytosine by PCR-based genomic sequencing. , 1994, BioTechniques.

[28]  T. Ushijima,et al.  The presence of a methylation fingerprint of Helicobacter pylori infection in human gastric mucosae , 2009, International journal of cancer.

[29]  S. Deutsch,et al.  Epigenetic Therapeutic Strategies for the Treatment of Neuropsychiatric Disorders: Ready for Prime Time? , 2008, Clinical neuropharmacology.

[30]  Manel Esteller,et al.  Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies , 2009, The Lancet Neurology.

[31]  A. Terzic,et al.  A study of microRNAs in silico and in vivo: diagnostic and therapeutic applications in cancer , 2009, The FEBS journal.

[32]  M. Endres,et al.  Folic acid, neurodegenerative and neuropsychiatric disease. , 2009, Current molecular medicine.

[33]  Qinghua Feng,et al.  Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Tim Hui-Ming Huang,et al.  Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  F. Patel,et al.  Utility of Gene Promoter Methylation in Prediction of Response to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) , 2009, Cancer investigation.

[36]  A. Jamurtas,et al.  Cell-free plasma DNA as a novel marker of aseptic inflammation severity related to exercise overtraining. , 2006, Clinical chemistry.

[37]  Robert Brown,et al.  Aberrant DNA methylation in ovarian cancer: is there an epigenetic predisposition to drug response? , 2003, Annals of the New York Academy of Sciences.

[38]  A. V. Starikov,et al.  Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation , 2006, British Journal of Cancer.

[39]  Steven S. Smith,et al.  Recovery of bisulfite-converted genomic sequences in the methylation-sensitive QPCR , 2007, Nucleic acids research.

[40]  M. Paz,et al.  CpG Island Hypermethylation of the DNA Repair Enzyme Methyltransferase Predicts Response to Temozolomide in Primary Gliomas , 2004, Clinical Cancer Research.

[41]  J. Rogers,et al.  Epigenetic Differences in Cortical Neurons from a Pair of Monozygotic Twins Discordant for Alzheimer's Disease , 2009, PloS one.

[42]  T. Alonzo,et al.  Molecular Cancer BioMed Central Review , 2007 .

[43]  M. Hildebrandt,et al.  Increased Reelin Promoter Methylation Is Associated With Granule Cell Dispersion in Human Temporal Lobe Epilepsy , 2009, Journal of neuropathology and experimental neurology.

[44]  Y. Christen,et al.  Oxidative stress and Alzheimer disease. , 2000, The American journal of clinical nutrition.

[45]  K. Dardoufas,et al.  Cell‐free DNA and RNA in Plasma as a New Molecular Marker for Prostate and Breast Cancer , 2006, Annals of the New York Academy of Sciences.

[46]  J. Timmer,et al.  Microarray analysis reveals influence of the sesquiterpene lactone parthenolide on gene transcription profiles in human epithelial cells. , 2007, Life sciences.

[47]  Steven J Skates,et al.  A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. , 2009, Gynecologic oncology.

[48]  R. Hruban,et al.  An algorithmic approach to the diagnosis of pancreatic neoplasms. , 2009, Archives of pathology & laboratory medicine.

[49]  Liz Y. Han,et al.  Circulating cell-free DNA: A novel biomarker for response to therapy in ovarian carcinoma , 2006, Cancer biology & therapy.

[50]  L. E. McDonald,et al.  A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[51]  A. Fischer,et al.  The epigenetic bottleneck of neurodegenerative and psychiatric diseases , 2009, Biological chemistry.

[52]  James T. Wu,et al.  Cell-free DNA: measurement in various carcinomas and establishment of normal reference range. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[53]  H. Powers,et al.  Folate Status and Aberrant DNA Methylation Are Associated With HPV Infection and Cervical Pathogenesis , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[54]  M. DePamphilis,et al.  Identifying 5-methylcytosine and related modifications in DNA genomes. , 1998, Nucleic acids research.

[55]  Y. Kwong,et al.  The study of p16 and p15 gene methylation in head and neck squamous cell carcinoma and their quantitative evaluation in plasma by real-time PCR. , 2003, European journal of cancer.

[56]  M. Chatterjee,et al.  Discovery of antibody biomarkers using protein microarrays of tumor antigens cloned in high throughput. , 2009, Methods in molecular biology.

[57]  Vishnu Swarup,et al.  Circulating (cell‐free) nucleic acids – A promising, non‐invasive tool for early detection of several human diseases , 2007, FEBS letters.

[58]  R. Chiu,et al.  Detection of circulating fetal nucleic acids: a review of methods and applications , 2009, Journal of Clinical Pathology.

[59]  Christopher J. Nelson,et al.  Advantages of next-generation sequencing versus the microarray in epigenetic research. , 2009, Briefings in functional genomics & proteomics.

[60]  A. Guidotti,et al.  GABAergic promoter hypermethylation as a model to study the neurochemistry of schizophrenia vulnerability , 2009, Expert review of neurotherapeutics.

[61]  R. Abrams,et al.  Differential methylation of cell‐free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis , 2010, Cancer.

[62]  H. Putter,et al.  Quantitative analysis of methylation of genomic loci in early-stage rectal cancer predicts distant recurrence. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  A. Bird.  The methyl-CpG-binding protein MeCP2 and neurological disease. , 2008, Biochemical Society transactions.

[64]  John H. Wilson,et al.  Instability and chromatin structure of expanded trinucleotide repeats. , 2009, Trends in genetics : TIG.

[65]  K. Kosaki,et al.  Diagnosis of Russell-Silver syndrome by the combined bisulfite restriction analysis-denaturing high-performance liquid chromatography assay. , 2009, Genetic testing and molecular biomarkers.

[66]  G. Fan,et al.  The role of DNA methylation in the central nervous system and neuropsychiatric disorders. , 2009, International review of neurobiology.

[67]  Robert S Illingworth,et al.  CpG islands – ‘A rough guide’ , 2009, FEBS letters.

[68]  R. Getzenberg,et al.  Biomarkers for prostate cancer , 2009, Journal of cellular biochemistry.

[69]  S. Sukumar,et al.  Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. , 2001, Oncogene.

[70]  S. Benlloch,et al.  Potential diagnostic value of methylation profile in pleural fluid and serum from cancer patients with pleural effusion , 2006, Cancer.

[71]  R. Büttner,et al.  CpG Island hypermethylation in cell‐free serum DNA identifies patients with localized prostate cancer , 2008, The Prostate.

[72]  P. Albers,et al.  CpG island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer. , 2009, The Journal of urology.

[73]  Christoph Grunau,et al.  Bisulfite genomic sequencing: systematic investigation of critical experimental parameters , 2001, Nucleic Acids Res..

[74]  Sandya Liyanarachchi,et al.  Prognostic DNA Methylation Biomarkers in Ovarian Cancer , 2006, Clinical Cancer Research.

[75]  S. Clark,et al.  Detection and measurement of PCR bias in quantitative methylation analysis of bisulphite-treated DNA. , 1997, Nucleic acids research.

[76]  Quantitative Multiplex Methylation-Specific PCR Assay for the Detection of Promoter Hypermethylation in Multiple Genes in Breast Cancer , 2004, Cancer Research.

[77]  I. Wistuba,et al.  Decitabine Effect on Tumor Global DNA Methylation and Other Parameters in a Phase I Trial in Refractory Solid Tumors and Lymphomas , 2009, Clinical Cancer Research.

[78]  D. Matei,et al.  Minireview: epigenetic changes in ovarian cancer. , 2009, Endocrinology.

[79]  S. Sukumar,et al.  Hypermethylation of 14-3-3 σ (stratifin) is an early event in breast cancer , 2001, Oncogene.

[80]  P. Delvenne,et al.  DNA methylation and cancer diagnosis: new methods and applications , 2009, Expert review of molecular diagnostics.

[81]  Nobuyuki Tani,et al.  Circulating cell-free mRNA in plasma as a tumor marker for patients with primary and recurrent gastric cancer. , 2007, Anticancer research.

[82]  A. Toland,et al.  Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment. , 2009, Seminars in cancer biology.

[83]  Luca Regli,et al.  Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide , 2004, Clinical Cancer Research.

[84]  Martin Widschwendter,et al.  Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. , 2005, Cancer research.